Akash Tewari
Stock Analyst at Jefferies
(4.71)
# 757
Out of 5,058 analysts
507
Total ratings
55.8%
Success rate
11.7%
Average return
Main Sectors:
Stocks Rated by Akash Tewari
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ETRA Electra Therapeutics | Initiated Coverage: Buy | $32 | $8.75 | +265.71% | 1 | Oct 13, 2026 | |
| BMY Bristol-Myers Squibb Company | Reiterated: Buy | $68 → $76 | $60.57 | +25.47% | 14 | Oct 12, 2026 | |
| PFE Pfizer | Reiterated: Buy | $35 → $36 | $29.44 | +22.28% | 47 | Oct 8, 2026 | |
| REGN Regeneron Pharmaceuticals | Reiterated: Buy | $890 → $930 | $796.34 | +16.78% | 36 | Oct 1, 2026 | |
| NBIX Neurocrine Biosciences | Reiterated: Buy | $200 → $220 | $136.95 | +60.64% | 30 | Sep 29, 2026 | |
| VRTX Vertex Pharmaceuticals | Reiterated: Buy | $633 → $640 | $508.75 | +25.80% | 5 | Sep 23, 2026 | |
| ALKS Alkermes | Reiterated: Buy | $78 → $83 | $40.10 | +106.98% | 30 | Sep 22, 2026 | |
| LLY Eli Lilly and Company | Reiterated: Buy | $1,440 | $1,251.61 | +15.05% | 47 | Sep 22, 2026 | |
| BNTX BioNTech SE | Reiterated: Buy | $138 | $90.20 | +52.99% | 40 | Sep 15, 2026 | |
| SYRE Spyre Therapeutics | Reiterated: Buy | $98 → $126 | $80.10 | +57.30% | 6 | Sep 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $50 | $14.76 | +238.75% | 1 | Sep 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $104 → $105 | $56.05 | +87.33% | 39 | Aug 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 | $18.74 | +166.81% | 2 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $40 → $48 | $13.76 | +248.84% | 3 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $90 | $44.12 | +103.99% | 10 | Jul 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $180 | $157.37 | +14.38% | 2 | May 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 | $2.78 | +403.60% | 1 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $350 | $434.03 | -19.36% | 2 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $980 → $1,008 | $846.27 | +19.11% | 42 | Feb 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 → $46 | $62.83 | -26.79% | 19 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $26 → $35 | $12.48 | +180.45% | 2 | Dec 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $13 → $42 | $25.75 | +63.11% | 6 | Nov 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $18 → $20 | $11.47 | n/a | 8 | Oct 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $70 → $80 | $63.92 | n/a | 19 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $398 → $502 | $459.81 | n/a | 16 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $138 | $145.19 | n/a | 34 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $52 → $10 | $7.16 | n/a | 8 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $183 | $214.42 | n/a | 18 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $6 → $2.5 | $2.24 | n/a | 7 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $16 → $17 | $17.30 | n/a | 7 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $17 | $1.76 | n/a | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $18.22 | n/a | 2 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $8.98 | n/a | 2 | Jan 29, 2020 |
Electra Therapeutics
Oct 13, 2026
Initiated Coverage: Buy
Price Target: $32
Current: $8.75
Upside: +265.71%
Bristol-Myers Squibb Company
Oct 12, 2026
Reiterated: Buy
Price Target: $68 → $76
Current: $60.57
Upside: +25.47%
Pfizer
Oct 8, 2026
Reiterated: Buy
Price Target: $35 → $36
Current: $29.44
Upside: +22.28%
Regeneron Pharmaceuticals
Oct 1, 2026
Reiterated: Buy
Price Target: $890 → $930
Current: $796.34
Upside: +16.78%
Neurocrine Biosciences
Sep 29, 2026
Reiterated: Buy
Price Target: $200 → $220
Current: $136.95
Upside: +60.64%
Vertex Pharmaceuticals
Sep 23, 2026
Reiterated: Buy
Price Target: $633 → $640
Current: $508.75
Upside: +25.80%
Alkermes
Sep 22, 2026
Reiterated: Buy
Price Target: $78 → $83
Current: $40.10
Upside: +106.98%
Eli Lilly and Company
Sep 22, 2026
Reiterated: Buy
Price Target: $1,440
Current: $1,251.61
Upside: +15.05%
BioNTech SE
Sep 15, 2026
Reiterated: Buy
Price Target: $138
Current: $90.20
Upside: +52.99%
Spyre Therapeutics
Sep 9, 2026
Reiterated: Buy
Price Target: $98 → $126
Current: $80.10
Upside: +57.30%
Sep 1, 2026
Initiated Coverage: Buy
Price Target: $50
Current: $14.76
Upside: +238.75%
Aug 31, 2026
Reiterated: Buy
Price Target: $104 → $105
Current: $56.05
Upside: +87.33%
Aug 11, 2026
Reiterated: Buy
Price Target: $50
Current: $18.74
Upside: +166.81%
Aug 11, 2026
Reiterated: Buy
Price Target: $40 → $48
Current: $13.76
Upside: +248.84%
Jul 15, 2026
Reiterated: Buy
Price Target: $90
Current: $44.12
Upside: +103.99%
May 22, 2026
Reiterated: Buy
Price Target: $180
Current: $157.37
Upside: +14.38%
Apr 30, 2026
Reiterated: Buy
Price Target: $14
Current: $2.78
Upside: +403.60%
Mar 10, 2026
Initiated Coverage: Hold
Price Target: $350
Current: $434.03
Upside: -19.36%
Feb 19, 2026
Reiterated: Buy
Price Target: $980 → $1,008
Current: $846.27
Upside: +19.11%
Dec 11, 2025
Reiterated: Buy
Price Target: $50 → $46
Current: $62.83
Upside: -26.79%
Dec 5, 2025
Reiterated: Buy
Price Target: $26 → $35
Current: $12.48
Upside: +180.45%
Nov 17, 2025
Reiterated: Buy
Price Target: $13 → $42
Current: $25.75
Upside: +63.11%
Oct 1, 2025
Upgraded: Buy
Price Target: $18 → $20
Current: $11.47
Upside: n/a
Sep 3, 2025
Reiterated: Buy
Price Target: $70 → $80
Current: $63.92
Upside: n/a
Aug 12, 2025
Reiterated: Buy
Price Target: $398 → $502
Current: $459.81
Upside: n/a
Jun 18, 2025
Reiterated: Buy
Price Target: $138
Current: $145.19
Upside: n/a
May 2, 2025
Downgraded: Hold
Price Target: $52 → $10
Current: $7.16
Upside: n/a
Apr 1, 2025
Reiterated: Buy
Price Target: $183
Current: $214.42
Upside: n/a
Jan 29, 2025
Reiterated: Hold
Price Target: $6 → $2.5
Current: $2.24
Upside: n/a
Dec 11, 2024
Rated: Buy
Price Target: $16 → $17
Current: $17.30
Upside: n/a
Dec 12, 2022
Initiated Coverage: Buy
Price Target: $17
Current: $1.76
Upside: n/a
Feb 26, 2021
Downgraded: Hold
Price Target: n/a
Current: $18.22
Upside: n/a
Jan 29, 2020
Downgraded: Hold
Price Target: n/a
Current: $8.98
Upside: n/a